Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
[47] Filippatos TD, Panagiotopoulou TV, Elisaf MS
Accumulating evidence suggests that vitamin Ds effect on glucose metabolism likely complements semaglutides mechanisms, particularly in enhancing insulin sensitivity and reducing fasting glucose levels
Diakses pada 10 Maret 2024.
After adding the water, do not shake the vial
If I were to want to get a prescription for a GLP-1, I would definitely go with Willow, as I know they would approve me